http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-086686-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_682d6117f1aef86a7b2b9af096d7d98a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4725 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 |
| filingDate | 2012-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-086686-A1 |
| titleOfInvention | COMPOSITIONS AND METHODS TO TREAT, CONTROL, REDUCE, OR RELIEF INFLAMMATORY PAIN |
| abstract | A composition for treating, controlling, reducing or relieving inflammatory pain comprises a dissociated glucocorticoid receptor agonist ("DIGRA"), a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable ester thereof. The composition may comprise an additional anti-inflammatory agent and may be formulated as a topical application, injection or implant. It can be used in a post-surgical eye pain control method in a way that reduces the risk of generating adverse side effects that do appear with other therapeutic agents. Claim 1: A composition comprising: (a) pharmaceutically acceptable carrier; and (b) a dissociated glucocorticoid receptor agonist ("DIGRA"), a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable ester thereof, in an amount effective to treat, control, reduce or alleviate the inflammatory pain in a subject, where DIGRA comprises a compound having the formula (1) where A and Q are independently selected from the group consisting of unsubstituted and substituted aryl and heteroaryl groups, unsubstituted and substituted cycloalkyl and heterocycloalkyl groups, cycloalkenyl groups and unsubstituted and substituted heterocycloalkenyl, unsubstituted and substituted cycloalkynyl and heterocycloalkynyl groups, and unsubstituted and substituted heterocyclic groups; R1 and R2 are independently selected from the group consisting of hydrogen, unsubstituted linear or branched C1-15 alkyl groups, substituted linear or branched C1-15 alkyl groups, unsubstituted C3-15 cycloalkyl groups, and substituted C3-15 cycloalkyl groups; R3 is one of the group consisting of hydrogen, unsubstituted linear or branched C1-15 alkyl groups, substituted linear or branched C1-15 alkyl groups, unsubstituted C3-15 cycloalkyl and heterocycloalkyl groups, substituted C3-15 cycloalkyl and heterocycloalkyl groups, groups aryl, heteroaryl groups, and heterocyclyl groups; B comprises a carbonyl, amino, divalent hydrocarbon, or heterohydrocarbon group; E is hydroxy or amino group; and D is absent or comprises a carbonyl group, -NH-, or -NR'-, where R 'comprises a linear or branched, unsubstituted or substituted C1-15 alkyl group; and where R1 and R2 can together form an unsubstituted or substituted C3-15 cycloalkyl group. Claim 10: The composition according to claim 2, wherein the DIGRA has the formula (2) wherein R4 and R5 are independently selected from the group consisting of hydrogen, halogen, cyano, hydroxy, C1-5 alkoxy groups, C1- alkyl groups 5 unsubstituted linear or branched branches, substituted linear or branched C1-5 alkyl groups, unsubstituted cyclic C3-10 alkyl groups, and substituted cyclic C3-10 alkyl groups. Claim 11: The composition according to claim 2, wherein the DIGRA has the formula (3) wherein R4 and R5 are independently selected from the group consisting of hydrogen, halogen, cyano, hydroxy, C1-5 alkoxy groups, C1- alkyl groups 5 unsubstituted linear or branched branches, substituted linear or branched C1-5 alkyl groups, unsubstituted cyclic C3-10 alkyl groups, and substituted cyclic C3-10 alkyl groups. Claim 12: The composition according to claim 2, wherein the DIGRA has the formula (4). |
| priorityDate | 2011-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 22.